drugset / Trial / NCT05498181

Angiotensin-Neprilysin Inhibition in Hemodialysis Initiation

NCT05498181

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This randomized placebo-controlled clinical trial will evaluate the effect of sacubitril/valsartan (compared with placebo) on echocardiographic measures of hypervolemia, preservation of residual renal function, and key safety parameters in incident hemodialysis patients.

Timeline

Start
2022-10-11
Primary completion
2026-01-31
Completion
2026-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril-Valsartan Unknown

Indications

No indication recorded.